Tritium labeled ketamine metabolites (R-ketamine, S-ketamine and RR-HNK)
Closed Solicitation Posted
- Solicitation number
- 25-004566
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541380 Testing Laboratories and Services
- Place of performance
- Maryland 20850, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institutes of Health (NIH), specifically the National Center for Advancing Translational Sciences (NCATS), is seeking to procure tritium-labeled ketamine metabolites including R-ketamine, S-ketamine, and 2R,6R-HNK (RR-HNK). The procurement is part of a bioactive small molecule project focused on advancing the study of RR-HNK from both mechanistic and pharmacological perspectives. The specific requirement calls for 5 mCi each of tritium-labeled R-ketamine, S-ketamine, and 2R,6R-HNK to support autoradiography work within NCATS' RR-HNK research program. The work must be completed within five months from contract award. The solicitation was posted on August 26, 2025, with proposals due by September 9, 2025, providing potential contractors with approximately two weeks to prepare their submissions.
This procurement does not utilize any set-aside designations and is open to all qualified contractors. No incumbent contractors or potential award values are specified in the solicitation notice. The contract requires delivery of precisely 5 mCi quantities of each of the three tritium-labeled compounds, representing specialized radiochemical materials essential for the NIH's translational research objectives. Performance will take place in Potomac, Maryland 20850, likely at NIH facilities or contractor locations serving the greater Washington D.C. metropolitan area. The procurement falls under NAICS code 541380 for Testing Laboratories and Services and PSC category B504 for Special Studies/Analysis-Chemical/Biological, indicating the specialized nature of the radiochemical synthesis and analytical services required.
Notice text
The National Institutes of Health (NIH) is the nation’s leading medical research agency and the primary Federal agency whose mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability, conducting, supporting and making medical discoveries that improve people’s health and save lives. The National Center for Advancing Translational Sciences (NCATS) is a translational science center that prides itself on its tremendously productive pipeline and is innovative in a number of ways. One of these ways is the development of new Bioactive Small Molecules which can modulate key biological pathways in multiple disease indications.
This bioactive small molecule project is one of the key projects that progresses the study of RR-HNK from a mechanistic and pharmacological perspective. The tritium labeled version of R-ketamine, S-ketamine and RR-HNK will provide key reagents for the study of the pharmacology of all 3 agents.
General description: Labeled R and S Ketamine and 2R,6R-HNK
Specific description: 5 mCi of R and S Ketamine and 2R,6R-HNK to conduct autoradiography work in support of our RR-HNK program.
Period of Performance is within five (5) months from the award of contract.
Files
| File | Type | Posted |
|---|---|---|
| PD - Novandi Ket and HNK order.docx | DOCX document |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity